{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:57:55Z","timestamp":1761649075814,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","doi-asserted-by":"publisher","award":["PTDC\/SAU-INF\/28080\/2017","EXPL\/SAU-INF\/1097\/2021","UIDB\/04138\/2020","UIDP\/04138\/2020"],"award-info":[{"award-number":["PTDC\/SAU-INF\/28080\/2017","EXPL\/SAU-INF\/1097\/2021","UIDB\/04138\/2020","UIDP\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT (via ImedULisboa)","doi-asserted-by":"publisher","award":["PTDC\/SAU-INF\/28080\/2017","EXPL\/SAU-INF\/1097\/2021","UIDB\/04138\/2020","UIDP\/04138\/2020"],"award-info":[{"award-number":["PTDC\/SAU-INF\/28080\/2017","EXPL\/SAU-INF\/1097\/2021","UIDB\/04138\/2020","UIDP\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Tuberculosis (TB) is currently one of the leading causes of death due to infective agents, and the growing rate of multidrug-resistant tuberculosis (MDR TB) cases poses an emergent public health threat. Fluoroquinolones are commonly used in the treatment of both MDR TB and drug-sensitive tuberculosis patients who are intolerant to first-line antitubercular agents. Unfortunately, these drugs have mild side effects, relevant to the prolonged treatment regimens and diminished bioavailability due to binding of metal ions. Moreover, the resistance to fluoroquinolones is also on the rise, a characteristic of extensively drug-resistant TB (XDR TB). Here, we developed esters as prodrugs of the fluoroquinolones levofloxacin and ciprofloxacin, with long-chain fatty alcohols. Both the alcohols and the quinolone have previously shown antimycobacterial activity and the aim was to develop esters with improved lipophilicity and capable of delivering the free acid inside mycobacterial cells. The carboxylic acid group of fluoroquinolones is essential to the mode of action but is also responsible for many of its side effects and metal-chelating properties. The synthesis, stability in biological media, and antibacterial activity were evaluated, the latter not only against Mycobacterium tuberculosis but also against other clinically relevant bacterial species, since the parent compounds display a broad spectrum of activity. The biological results show a reduction in the antitubercular activity of the synthesized derivatives, probably due to deficient activation of the ester prodrug. Despite this, it was found that the derivatives exhibit bioactivity against other fluoroquinolone-resistant bacteria, indicating a different mode of action and suggesting that it may be worthwhile to research further modifications to the carboxylic acid group. This might lead to new compounds that are efficient against resistant strains. This idea that the compounds may act by a different mechanism of action was further supported by a brief computer investigation that demonstrated the potential lack of selectivity of the esters to the fluoroquinolone target.<\/jats:p>","DOI":"10.3390\/ph15101213","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T01:21:07Z","timestamp":1665364867000},"page":"1213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fluoroquinolone Derivatives in the Treatment of Mycobacterium tuberculosis Infection"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-5913","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Pais","sequence":"first","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"given":"Margarida","family":"Policarpo","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-1516","authenticated-orcid":false,"given":"David","family":"Pires","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-2075","authenticated-orcid":false,"given":"Ana Paula","family":"Francisco","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"},{"name":"Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"given":"Ana Margarida","family":"Madureira","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"},{"name":"Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"given":"Bernard","family":"Testa","sequence":"additional","affiliation":[{"name":"University of Lausanne, 1015 Lausanne, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5934-0198","authenticated-orcid":false,"given":"Elsa","family":"Anes","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"},{"name":"Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-4830","authenticated-orcid":false,"given":"Lu\u00eds","family":"Constantino","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"},{"name":"Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021). Global Tuberculosis Report, World Health Organization."},{"key":"ref_2","unstructured":"World Health Organization (2020). WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, World Health Organization."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/molbev\/msz214","article-title":"The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium Tuberculosis","volume":"37","author":"Castro","year":"2020","journal-title":"Mol. Biol. Evol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijtb.2018.07.008","article-title":"Efflux Pump as Alternate Mechanism for Drug Resistance in Mycobacterium Tuberculosis","volume":"66","author":"Kanji","year":"2019","journal-title":"Indian J. Tuberc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/acsinfecdis.9b00019","article-title":"Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics","volume":"5","author":"Cheng","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ddr.21468","article-title":"Microbial Esterases and Ester Prodrugs: An Unlikely Marriage for Combating Antibiotic Resistance","volume":"80","author":"Larsen","year":"2019","journal-title":"Drug Dev. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3998\/ark.5550190.0010.c28","article-title":"Synthesis and Antibacterial Activity of 9-Cyclopropyl-4-Fluoro-6-Oxo-6,9- Dihydro-[1,2,5]Thiadiazolo [3,4-h]Quinoline-7-Carboxylic Acid and Its Ethyl Ester","volume":"2009","author":"Zahra","year":"2009","journal-title":"Arkivoc"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/157340610791321442","article-title":"Design of Ciprofloxacin Derivatives That Inhibit Growth of Methicillin Resistant Staphylococcus Aureus (MRSA) and Methicillin Susceptible Staphylococcus Aureus (MSSA)","volume":"6","author":"Bartzatt","year":"2010","journal-title":"Med. Chem."},{"key":"ref_11","first-page":"554","article-title":"Effect of Aluminium Ion on Bioavailability of Levofloxacin Following Oral Administration of Cilexetil Ester of Levofloxacin as Prodrug in Rats","volume":"75","author":"Shinmachi","year":"2020","journal-title":"Pharmazie"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/slct.201600091","article-title":"Facile Synthesis of Ciprofloxacin Prodrug Analogues to Improve Its Water Solubility and Antibacterial Activity","volume":"1","author":"Assali","year":"2016","journal-title":"ChemistrySelect"},{"key":"ref_13","first-page":"517","article-title":"Synthesis and Preliminary Pharmaceutical Evaluation of New Polymeric Prodrug of Levofloxacin as a Drug Delivery System","volume":"64","author":"Saleh","year":"2020","journal-title":"Egypt. J. Chem."},{"key":"ref_14","first-page":"1301","article-title":"Moxifloxacin-Ester Derivatives: Synthesis, Characterization and Pharmacological Evaluation","volume":"32","author":"Akhtar","year":"2019","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/1574-6968.12043","article-title":"Antibacterial Activity of Long-Chain Fatty Alcohols against Mycobacteria","volume":"338","author":"Mukherjee","year":"2013","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.tet.2018.12.021","article-title":"The Journey of Total Synthesis toward Nannocystin Ax","volume":"75","author":"Liu","year":"2019","journal-title":"Tetrahedron"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e202200120","DOI":"10.1002\/anie.202200120","article-title":"Peptide Backbone Directed Self-Assembly of Merocyanine Oligomers into Duplex Structures","volume":"61","author":"Liu","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C8CS00096D","article-title":"\u201cchemistry-on-the-Complex\u201d: Functional RuII Polypyridyl-Type Sensitizers as Divergent Building Blocks","volume":"47","author":"Mede","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10822-005-8694-y","article-title":"Virtual computational chemistry laboratory-design and description","volume":"19","author":"Tetko","year":"2005","journal-title":"J Comput. Aid. Mol. Des."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.mimet.2011.02.003","article-title":"Development of a Method to Investigate the Hydrolysis of Xenobiotic Esters by a Mycobacterium Smegmatis Homogenate","volume":"85","author":"Valente","year":"2011","journal-title":"J. Microbiol. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Software News and Updates AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1128\/AAC.00936-15","article-title":"Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium Tuberculosis and Other Naturally Resistant Mycobacteria in Vitro and Ex Vivo within Macrophages","volume":"59","author":"Pires","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105831","DOI":"10.1016\/j.ejps.2021.105831","article-title":"Activation of Benzoate Model Prodrugs by Mycobacteria. Comparison with Mammalian Plasma and Liver Hydrolysis","volume":"162","author":"Valente","year":"2021","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/10\/1213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:25Z","timestamp":1760143465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/10\/1213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ph15101213"],"URL":"https:\/\/doi.org\/10.3390\/ph15101213","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}